Quick Answer
Forte Biosciences, Inc. reported Stockholders Equity of $60.99 million for fiscal year 2025.
Forte Biosciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $60.99M | +16.2% |
| 2024 | $52.48M | +48.6% |
| 2023 | $35.31M | -9.0% |
| 2022 | $38.82M | -6.6% |
| 2021 | $41.55M | -29.6% |
| 2020 | $58.98M | +1336.7% |
| 2019 | -$4.77M | -548.0% |
| 2018 | -$736.0K | -101.0% |
| 2017 | $71.08M | +157.1% |
| 2016 | -$124.42M | -34.8% |
| 2015 | -$92.33M | -31.1% |
| 2014 | -$70.44M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $84.10M | +797.9% | -14.7% |
| June 30, 2025 | $98.61M | +481.4% | +156.6% |
| March 31, 2025 | $38.43M | +34.0% | -26.8% |
| December 31, 2024 | $52.48M | +48.6% | +460.3% |
| September 30, 2024 | $9.37M | -76.8% | -44.8% |
| June 30, 2024 | $16.96M | -31.8% | -40.9% |
| March 31, 2024 | $28.68M | -12.9% | -18.8% |
| December 31, 2023 | $35.31M | -9.0% | -12.6% |
- Forte Biosciences, Inc. showed an increase of +16.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2014–2025 period, Forte Biosciences, Inc.’s stockholders equity has grown by 186.6% (from -$70.44 million to $60.99 million).
- The most recent figure is from Forte Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: